Results 61 to 70 of about 186,086 (209)
Chronic Myeloid Leukemia in 2020
HemaSphere, 2020 AbstractNew insights have emerged from maturing long‐term academic and commercial clinical trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of response has unexpectedly proved less important than hitherto thought, does not predict survival, and is of unclear relevance for treatment‐free remission (TFR).
openaire +3 more sources
Advanced Science, EarlyView.Overview of the regulation of intrinsic and extrinsic signals during neurodevelopment. Intrinsic genetic signals from NSCs, in conjunction with cues from microglia and blood vessels, collaboratively regulate the proliferation of NSCs, their fate determination, synaptogenesis, synaptic pruning, neuronal survival, and death, as well as communication ...
Yanyan Wang +4 more
wiley +1 more source
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]
, 2019 Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M +4 more
core +1 more source
Recent Advances in mRNA Delivery Systems for Cancer Therapy
Advanced Science, EarlyView.This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang +9 more
wiley +1 more source
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
, 2011 BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem +19 more
core +1 more source
miRNAs in acute myeloid leukemia
Oncotarget, 2016 MicroRNAs (miRNAs) are small, non-coding RNAs found throughout the eukaryotes that control the expression of a number of genes involved in commitment and differentiation of hematopoietic stem cells and tumorigenesis. Widespread dysregulation of miRNAs have been found in hematological malignancies, including human acute myeloid leukemia (AML).
Xia Li +4 more
openaire +4 more sources
SMC4 Promotes Prostate Cancer Cell Proliferation and Metastasis via the Rheb/mTOR Pathway
Advanced Science, EarlyView.Structural maintenance of chromosome protein 4 (SMC4) has been implicated in prostate cancer metastasis. Knockdown of SMC4 in RM1‐LM cells significantly attenuates proliferation, migration, and lung metastasis in vivo. Furthermore, SMC4 interacts with GLUT1 (Slc2a1), thereby enhancing glycolysis, ATP production, and activation of the Rheb/mTOR pathway.
Wei Zhang +9 more
wiley +1 more source
Hepatology, EarlyView., 2022 KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou +15 more
wiley +1 more source
Overexpression of the protein kinase CK2 increases the survival and resistance to chemotherapy of acute myeloid leukemia cells [PDF]
, 2013 Background: The critical role of protein kinase CK2 in the regulation of cellular apoptosis suggests its may be involvement in tumor cell resistance to both conventional and unconventional therapies.
PAVAN, LAURA
core +1 more source
Biological aspects of mTOR in leukemia [PDF]
, 2018 The mammalian target of rapamycin (mTOR) is a central processor of intra-and extracellular signals, regulating many fundamental cellular processes such as metabolism, growth, proliferation, and survival.
Bianchi, Mp +5 more
core +1 more source